BH-30236
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BH-30236, covering 2025-09-24 to 2025-09-24. Get the full timeline:
Most recent: Clinical Trial Update: A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome [Phase 1]